A Phase 3 interventional study of Gestodene/EE Patch (BAY86-5016) in Contraception, sponsored by Bayer. Completed at 63 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is examining a birth control patch for 13 cycles (1 year).
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gestodene/EE Patch (BAY86-5016)
Drug pages: Gestodene · Ethinyl Estradiol
55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
Occurrence of pregnancy (yes/no) while on treatment
Time frame: 13 treatment cycles each consisting of 28 days and follow-up period of 14 days
Vital signs
Time frame: 13 treatment cycles each consisting of 28 days
Physical and gynecological examinations
Time frame: 13 treatment cycles each consisting of 28 days
Laboratory assessments
Time frame: 13 treatment cycles each consisting of 28 days
Adverse events (AE monitoring)
Time frame: 13 treatment cycles each consisting of 28 days
Ran from May 2009 to primary completion in Dec 2010, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gestodene · Ethinyl Estradiol